


Listing of Claims

Claims 1 - 39 have been canceled without prejudice, and claims 40 - 51 have been added as follows. This listing of claims will replace all prior versions and listings of claims in the application.

1. – 39. (Cancelled)

40. (New) A compound according to structural formula (I):



including pharmaceutically acceptable salts thereof, wherein:

$N-R^1-C(O)$ is a polyene macrolide backbone;

CH_2-R^2 is a carbohydrate residue, where the illustrated CH_2 is derived from the anomeric carbon of a terminal carbohydrate saccharide and R^2 represents the remainder of the carbohydrate;

either: (i) R^6 is selected from the group consisting of hydrogen, (C_1-C_6) alkyl substituted with one or more of the same or different R^{10} groups, $-[(CH_2)_n-NH]_p-(CH_2)_n-NR^{15}R^{16}$, $-[(CH_2)_n-NH]_p-(CH_2)_p-NR^{15}R^{16}$, $-NH-[(CH_2)_n-NH]_p-(CH_2)_p-NR^{15}R^{16}$, $-[(CH_2)_n-NH]_p-(CH_2)_n-R^{17}$ and $-NH-[(CH_2)_n-NH]_p-(CH_2)_p-R^{17}$ and R^7 is selected from the group consisting of (C_1-C_6) alkyl substituted with one or more of the same or different R^{10} groups, $-[(CH_2)_n-NH]_p-(CH_2)_n-NR^{15}R^{16}$, $-[(CH_2)_n-NH]_p-(CH_2)_p-NR^{15}R^{16}$, $-NH-[(CH_2)_n-NH]_p-(CH_2)_p-NR^{15}R^{16}$, $-[(CH_2)_n-NH]_p-(CH_2)_n-R^{17}$ and $-NH-[(CH_2)_n-NH]_p-(CH_2)_p-R^{17}$; or

(ii) R^6 and R^7 , taken together with the nitrogen atom to which they are bonded, form a 5- or 6-membered saturated or unsaturated ring which optionally

includes one or more of the same or different additional heteroatoms selected from the group consisting of O, N, NH, and S and which is substituted at one or more ring carbon or heteroatoms with the same or different substituents selected from the group consisting of R^{11} , (C₁-C₆) alkyl, (C₁-C₆) alkoxy, $-(CH_2)_n-R^{11}$, (C₅-C₆) aryl, phenyl, 6- to 9-membered arylalkyl and benzyl;

each R^{10} is independently selected from the group consisting of =O (oxo), =NH (imino), $-C(=NH)-NH_2$ (amidino), and $-NH-C(=NH)-NH_2$ (guanidino);

each R^{11} is independently selected from the group consisting of -OH, =O (oxo), $-NH_2$ (amino), =NH (imino), $-C(=NH)-NH_2$ (amidino), and $-NH-C(=NH)-NH_2$ (guanidino);

R^{14} is hydrogen or alkyl;

either: (i) R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl and (C₁-C₆) alkyl independently substituted with one or more of the same or different R^{11} groups; or

(ii) R^{15} and R^{16} , taken together with the nitrogen atom to which they are bonded, form a 5- or 6-membered saturated or unsaturated ring which optionally includes one or more of the same or different additional heteroatoms selected from the group consisting of O, N, NH and S and which is optionally substituted at one or more ring carbon or heteroatoms with the same or different substituents selected from the group consisting of R^{11} , (C₁-C₆) alkyl, (C₁-C₆) alkoxy, $-(CH_2)_n-R^{11}$, (C₅-C₆) aryl, phenyl, 6- to 9-membered arylalkyl and benzyl;

R^{17} is a 5- or 6-membered saturated or unsaturated ring including one or more of the same or different heteroatoms selected from the group consisting of O, N, NH and S and which is optionally substituted at one or more ring carbon or heteroatoms with the same or different substituents selected from the group consisting of R^{11} , (C₁-C₆) alkyl, (C₁-C₆) alkoxy, $-(CH_2)_n-R^{11}$, (C₅-C₆) aryl, phenyl, 6- to 9-membered arylalkyl and benzyl;

each n is independently an integer from 1 to 6; and

each p is independently an integer from 0 to 6.

41. (New) The compound of claim 40 wherein R^6 and R^7 are defined according to alternative (i).

42. (New) The compound of claim 40 wherein R^6 and R^7 are defined according to alternative (ii).

43. (New) The compound of claim 40 which has one or more features selected from the group consisting of:

$N-R^1-C(O)$ is a polyene backbone derived from AmB or nystatin;

CH_2-R^2 is a mono-, di- or oligosaccharide;

R^6 is hydrogen; and

R^{14} is hydrogen.

44. (New) The compound of claim 40 wherein:

R^6 is hydrogen;

R^7 is selected from the group consisting of $-(CH_2)_n-NR^{15}R^{16}$, $-(CH_2)_n-R^{17}$ and (C_1-C_6) alkyl substituted with one or more of the same or different R^{10} groups;

R^{15} and R^{16} , taken together with the nitrogen atom to which they are bonded, form a 5- or 6-membered saturated or unsaturated ring which optionally includes one or more additional heteroatoms selected from the group consisting of O, S, N and NH, and/or which is optionally substituted at one or more ring carbon or heteroatoms with the same or different R^{10} , (C_1-C_6) alkyl, (C_1-C_6) alkoxy, (C_5-C_6) aryl, phenyl, 6- to 9-membered arylalkyl or benzyl groups; and

R^{17} is a 5- or 6-membered heteroaryl which is optionally substituted with one or more of the same or different (C_1-C_6) alkyl, (C_1-C_6) alkoxy, (C_5-C_6) aryl, phenyl, 6- to 9-membered arylalkyl or benzyl groups.

45. (New) The compound of claim 40 wherein:

either: (i) R^6 and R^7 , taken together with the nitrogen atom to which they are bonded, form a 5- to 6-membered cycloheteroalkyl ring which is optionally substituted with one or more substituent selected from the group consisting of (C₁-C₆) alkyl, (C₁-C₆) alkoxy, $-(CH_2)_n-R^{11}$, (C₅-C₆) aryl, phenyl, 6- to 9-membered arylalkyl and benzyl, wherein the heteroatoms are O or S; or

(ii) R^6 and R^7 , taken together with the nitrogen atom to which they are bonded, form a 5- to 6-membered cycloheteroalkyl ring which is substituted with one or more substituent selected from the group consisting of (C₁-C₆) alkyl, (C₁-C₆) alkoxy, $-(CH_2)_n-R^{11}$, (C₅-C₆) aryl, phenyl, 6- to 9-membered arylalkyl and benzyl; and

R^{11} is amino or hydroxy.

46. (New) The compound of claim 40 wherein substituent NR^6R^7 is contributed by any amine selected from the group consisting of 1-amino-4-methylpiperazine, 2-(2-aminoethyl) pyridine, 3-amino-5-methylisoxazole, 1-amino-1-deoxy-D-sorbitol, 4-(3-aminopropyl) morpholine, 3-amino-1,2-propanediol, 1-methylpiperazine, 1-(2-aminoethyl) piperidine, 2-(thiophen-2-yl) ethylamine, 1-(3-aminopropyl)-2-pyrrolidinone, triethylenetetramine, 1-ethyl-piperazine, 1-benzyl-piperazine, 1-(ethan-2-ol)-piperazine, 1-phenyl piperazine, morpholine, D-glucoseamine(HCl), D-galactoseamine(HCl), and D-mannoseamine(HCl).

47. (New) A pharmaceutical composition comprising a compound according to any one of claims 40 to 46, and a pharmaceutically-acceptable carrier, excipient or diluent.

48. (New) A method of treating or preventing a fungal infection comprising administering to a subject in need thereof a compound according to claim 40 in an amount effective to treat or prevent a fungal infection.

49. (New) The method of claim 48 wherein the subject is a human, an animal or a plant.

50. (New) The method of claim 48 wherein the infection is a topical infection.

51. (New) The method of claim 48 wherein the infection is a systemic infection.